51. Scleroderma Clinical trials / Disease details

Clinical trials : 523 / Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

7 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02801305 (ClinicalTrials.gov)	June 2016	9/6/2016	Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers	Assessing and Comparing the Effect of Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers.	Digital Ulcer of Scleroderma	Drug: Diltiazem Gel 2%;Drug: Nitroglycerin Ointment 2%;Drug: Vaseline	Mohammad Ali Nazarinia	Shiraz University of Medical Sciences	Completed	20 Years	70 Years	All	90	Phase 2	Iran, Islamic Republic of
2	NCT00577304 (ClinicalTrials.gov)	December 2007	18/12/2007	A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon	A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon	Raynaud's Disease;Raynaud's Disease Secondary to Scleroderma;Raynaud's Disease Secondary to Other Autoimmune Disease	Drug: Nitroglycerin;Drug: Topical AmphiMatrix	MediQuest Therapeutics	NULL	Active, not recruiting	15 Years	70 Years	Both	200	Phase 3	United States
3	NCT00419419 (ClinicalTrials.gov)	December 2006	4/1/2007	Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon	Phase III In-Life Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon	Raynaud's Disease;Scleroderma;Autoimmune Diseases	Drug: Topical AmphiMatrix with nitroglycerin (MQX-503)	MediQuest Therapeutics	NULL	Completed	18 Years	70 Years	Both	80	Phase 3	United States;Sweden;United Kingdom
4	EUCTR2005-004979-37-GB (EUCTR)	27/11/2006	18/09/2006	Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon - 06-004 A2	Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon - 06-004 A2	Moderate to severe primary Raynaud’s, OR patients with Raynaud’s phenomenon secondary to autoimmune diseases, such as scleroderma	Product Name: MQX-503 Product Code: MQX-503 INN or Proposed INN: 10% Nitroglycerine in Propylene Glycol, USP Other descriptive name: Nitroglycerine gel	MediQuest Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	100	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United Kingdom;Sweden
5	EUCTR2005-004979-37-SE (EUCTR)	27/10/2006	08/09/2006	Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon - 06-004 A2	Phase III In-Life” Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud’s Phenomenon - 06-004 A2	Moderate to severe primary Raynaud’s,OR patients with Raynaud’s phenomenon secondary to autoimmune diseases, such as scleroderma	Product Name: MQX-503 Product Code: MQX-503 INN or Proposed INN: 10% Nitroglycerine in Propylene Glycol, USP Other descriptive name: Nitroglycerine gel	MediQuest Therapeutics, Inc.	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 3	United Kingdom;Sweden
6	NCT00378521 (ClinicalTrials.gov)	July 2006	18/9/2006	Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon	Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon	Raynaud's Disease;Raynaud's Disease Secondary to Scleroderma;Raynaud's Disease Secondary to Autoimmune Disease	Drug: MQX-503	MediQuest Therapeutics	NULL	Completed	18 Years	75 Years	Both	15	Phase 2	United States
7	NCT00253331 (ClinicalTrials.gov)	November 2004	13/11/2005	Lab Study of MQX-503 in Treatment of Raynaud's	Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud’s Phenomenon	Raynaud Disease;Raynaud Disease Secondary to Scleroderma;Raynaud Secondary to Other Autoimmune Disease	Drug: topical organogel with nitroglycerin	MediQuest Therapeutics	NULL	Completed	18 Years	80 Years	Both	36	Phase 2/Phase 3	United States